Serina Therapeutics (NYSEAMERICAN:SER) Posts Earnings Results

Serina Therapeutics (NYSEAMERICAN:SER) announced its quarterly earnings data on Thursday. The company reported ($0.58) EPS for the quarter, FiscalAI reports.

Serina Therapeutics Trading Down 4.7%

Shares of SER traded down $0.08 during trading hours on Friday, reaching $1.64. 156,583 shares of the company traded hands, compared to its average volume of 72,936. The firm has a fifty day moving average of $1.93. The firm has a market cap of $24.44 million, a PE ratio of -0.82 and a beta of 1.15. Serina Therapeutics has a 1-year low of $1.22 and a 1-year high of $7.92.

Insider Activity at Serina Therapeutics

In other news, insider Randall Moreadith sold 39,000 shares of the company’s stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $2.50, for a total transaction of $97,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 17.00% of the company’s stock.

Serina Therapeutics Company Profile

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.